Cargando…

Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies

AIMS: To determine the impact of race and ethnicity on the efficacy, body weight and hypoglycaemia incidence with vildagliptin treatment in patients with type 2 diabetes mellitus using patient‐level data from the vildagliptin clinical trial programme. METHODS: Data from 22 randomized, placebo‐contro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kozlovski, Plamen, Fonseca, Marilia, Mohan, Viswanathan, Lukashevich, Valentina, Odawara, Masato, Paldánius, Päivi M., Kothny, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516163/ https://www.ncbi.nlm.nih.gov/pubmed/27943546 http://dx.doi.org/10.1111/dom.12844

Ejemplares similares

Efficacy and Safety of a Single-Pill Combination of Vildagliptin and Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Odawara, Masato, et al.
Publicado: (2015)

Clinical Safety and Tolerability of Vildagliptin — Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance
por: Mathieu, Chantal, et al.
Publicado: (2017)

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
por: Kothny, Wolfgang, et al.
Publicado: (2015)

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment
por: Lukashevich, Valentina, et al.
Publicado: (2013)

Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus
por: Evans, Marc, et al.
Publicado: (2017)

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea
por: Lukashevich, V, et al.
Publicado: (2014)

Research: Treatment Study to determine the durability of glycaemic control with early treatment with a vildagliptin–metformin combination regimen vs. standard-of-care metformin monotherapy—the VERIFY trial: a randomized double-blind trial
por: Del Prato, S, et al.
Publicado: (2014)

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies
por: Schweizer, Anja, et al.
Publicado: (2011)

Clinical evidence and mechanistic basis for vildagliptin’s effect in combination with insulin
por: Schweizer, Anja, et al.
Publicado: (2013)

Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin — Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes
por: Strain, William David, et al.
Publicado: (2017)

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
por: Odawara, Masato, et al.
Publicado: (2014)

Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study
por: Williams, Rachael, et al.
Publicado: (2019)

Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan
por: Odawara, Masato, et al.
Publicado: (2016)

A pre‐specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM
por: Matthews, David R., et al.
Publicado: (2019)

Association between vildagliptin and risk of angioedema, foot ulcers, skin lesions, hepatic toxicity, and serious infections in patients with type 2 diabetes mellitus: A European multidatabase, noninterventional, postauthorization safety study
por: Williams, Rachael, et al.
Publicado: (2019)

Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study)
por: Suh, Sunghwan, et al.
Publicado: (2017)

Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017)

Surfing the Vildagliptin Tsunami
por: Balachandran, Karthik
Publicado: (2020)

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
por: Das, Sambit, et al.
Publicado: (2021)

Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin‐metformin combination in newly diagnosed Type 2 diabetes
por: Matthews, D. R., et al.
Publicado: (2019)

Effect of Vildagliptin on Hepatic Steatosis
por: Macauley, Mavin, et al.
Publicado: (2015)

Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation
por: Paldánius, Päivi Maria
Publicado: (2020)

Mild acute pancreatitis with vildagliptin use
por: Saraogi, Ravikant, et al.
Publicado: (2012)

Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
por: Wiciński, Michał, et al.
Publicado: (2020)

Dictionary of race and ethnic relations
por: Cashmore, Ernest
Publicado: (1994)

Race and ethnicity in Latin America /
por: Wade, Peter, 1957-
Publicado: (2010)

Race and ethnicity in Latin America /
por: Wade, Peter, 1957-
Publicado: (1997)

Dictionary of race and ethnic relations
por: Cashmore, Ernest
Publicado: (1996)

Race and ethnicity in research methods /
Publicado: (1993)

Error in Description of Race/Ethnicity
Publicado: (2020)

Adverse Childhood Experiences, Commitment Offense, and Race/Ethnicity: Are the Effects Crime-, Race-, and Ethnicity-Specific?
por: DeLisi, Matt, et al.
Publicado: (2017)

Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real-life worldwide observational study (EDGE)
por: Mathieu, C, et al.
Publicado: (2013)

A case of vildagliptin-induced interstitial pneumonia
por: Kuse, Naoyuki, et al.
Publicado: (2016)

Physicochemical Properties and Methods of Analysis of Vildagliptin (Review)
por: Polyakova, E. B., et al.
Publicado: (2022)

Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes
por: Matthews, David, et al.
Publicado: (2020)

Race/Ethnicity, Lipoproteins, and Antiretroviral Therapy
Publicado: (2006)

Revisiting the impact of race/ethnicity in endometriosis
por: Bougie, Olga, et al.
Publicado: (2022)

Race/Ethnicity and Reference Equations for Spirometry
por: Miller, Martin R., et al.
Publicado: (2022)

Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide
por: Kudo‐Fujimaki, Kyoko, et al.
Publicado: (2013)

Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers
por: Schnaars, Yvonne, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8fbn1hjcedlvhso6c2hq7lgoqv